OPEN LABEL MULTICENTER TRIAL OF ORAL CII TOLERANCE IN RA

RA 口服 CII 耐受性的开放标签多中心试验

• 批准号: 7375424
• 负责人: ARNOLD E POSTLETHWAITE
• 金额: $ 5.13万
• 依托单位: UNIVERSITY OF TENNESSEE HEALTH SCI CTR
• 依托单位国家: 美国
• 财政年份: 2005
• 资助国家: 美国
• 起止时间: 2005-12-01 至 2006-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7375424
• 关键词: OPEN; LABEL; MULTICENTER; TRIAL; ORAL

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This is a dose escalation study designed to determine whether specific doses of bovine CII will induce immune tolerance in patients with rheumatoid arthritis who will remain on their current treatment plans for DMARD, NSAID and prednis

该子项目是利用NIH/NCRR资助的中心赠款提供的资源的许多研究子项目之一。子项目和研究者（PI）可能从另一个NIH来源获得主要资金，因此可以在其他CRISP条目中表示。所列机构为中心，不一定是研究者所在机构。这是一项剂量递增研究，旨在确定特定剂量的牛CII是否会诱导类风湿性关节炎患者的免疫耐受，这些患者将继续接受目前的DMARD、NSAID和强的松治疗计划。